New cosmetics business combining stem cell technology and cosmetics technology
First written in FY2017-Q2. 2 of 5 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2022-Q2.
No other company in this theme has enough history to compare yet.
- FY2022-Q2Exclusion from the Equity-Method ScopeAnnual report
「From the second quarter of the current fiscal year, リプロキレート, formerly an equity-method affiliate, has been excluded from the scope of equity-method accounting because all of the shares it held were sold.」
All shares held in リプロキレート were sold, and the company was excluded from the scope of equity-method accounting. The filing does not specify how the cosmetics business will be handled going forward. - FY2018RestatedAnnual report
「Finally, リプロキレート社, our equity-method affiliate engaged in the cosmetics sales business, has begun selling its first product, “Cellarge Bio Mask.”」
In the cosmetics business utilizing stem cell culture technology, the company has confirmed its policy of continuing to develop new products after the launch of its first product. - FY2018-Q3AdvancedAnnual report
「リプロキレート社, our equity-method affiliate engaged in the cosmetics sales business, has begun selling its first product, “Cellarge Bio Mask.”」
In the cosmetics business applying stem cell culture technology, the company reached the specific commercialization milestone of the joint venture beginning sales of its first product. - FY2017-Q3AdvancedAnnual report
「We established リプロキレート社 as a joint venture to sell cosmetics applying stem cell culture technology, thereby entering the cosmetics business. The company is currently working toward commercializing products during fiscal 2017.」
The company’s entry into the cosmetics business through the joint venture was confirmed, with commercialization targeted for fiscal 2017. - FY2017-Q2First statedAnnual report
「Going forward, we will combine our stem cell technology with キレート社’s cosmetics development technology to develop new cosmetics. At the same time as advancing joint development with キレート社 concerning cosmetics and related products, we will establish リプロキレート社 as the sales company for the products developed.」
A joint venture, リプロキレート, was established by キレートジャパン and 昇陽, and began a new business involving the joint development and sale of cosmetics combining stem cell culture technology with freeze-drying and encapsulation technology. Capital is ¥30 million, with ownership of 35% by our company, 40% by キレートジャパン and 25% by 昇陽.